GB633175A — Antibiotic preparations and process for obtaining the same

USPTO Abstract

Clear aqueous solutions of tyrothricin, which are physically and bactericidally stable and are useful for medicinal and veterinary purposes (see Group VI), are manufactured by mixing an aqueous or alcoholic solution of a solubilizer, comprising a water-soluble salt of an organic quaternary ammonium compound having three alkyl groups of not more than 2 carbon atoms and one straight chain alkyl group of 12-18 carbon atoms attached directly to the nitrogen atom, with an alcoholic solution of tyrothricin, and, if necessary, diluting the resulting solution with water. The amount of solubilizer depends on the concentration of tyrothricin in the final solution, and varies between about 0.02-1.5 per cent. Examples describe the use as solubilizers of cetyltrimethylammonium acetate, chloride and bromide, n-dodecyltriethylammonium propionate, n-tetradecyldimethylethylammonium acetate and n-octadecyltrimethylammonium chloride.ALSO:Clear aqueous solutions of tyrothricin, which are physically and bactericidally stable and are useful for medicinal and veterinary purposes, are manufactured by mixing an aqueous or alcoholic solution of a solubilizer, comprising a water-soluble salt of an organic quaternary ammonium compound having three alkyl groups of not more than two carbon atoms and one straight chain alkyl group of 12-18 carbon atoms attached directly to the nitrogen atom, with an alcoholic solution of tyrothricin, and, if necessary, diluting the resulting solution with water. If desired there may be added an aqueous solution of a water-soluble salt of a vasoconstrictor, e.g., ephedrine, neosynephrin or the substances sold under the Registered Trade Marks "Epinephrim" and "Benzedrine." In examples: (1) an aqueous solution of cetyltrimethylammonium acetate is added to an alcoholic solution of tyrothricin and the mixture is diluted with water; the product is suitable for treating bovine mastitis by injection into the udder; (2) stronger solutions are employed, giving a product suitable for topical application to wounds, ulcers and abscesses, and for treatment of osteomyelitis and infections of the pleural cavity, nasal sinus and eye; (3) an alcoholic solution of tyrothricin is added to an alcoholic solution of cetyltrimethylammonium acetate, the mixture is added to an aqueous solution of ephedrine lactate containing sufficient dextrose to make the final preparation isotonic, and the solution is diluted with water; the product is useful as an inhalant for treating congested or infected nasal sinuses; (4) the solubilizer in (3) is replaced by the corresponding chloride and the proportions varied; (5) an alcoholic solution of cetyltrimethylammonium bromide is diluted with water and added to an alcoholic solution of tyrothricin and the product is further diluted; (6) an aqueous solution of n-dodecyltriethylammonium propionate is added to an alcoholic solution of tyrothricin and the mixture diluted; (7) the solubilizer in (6) is replaced by n-tetradecyldimethylethylammonium acetate, and (8) by n-octadecyltrimethylammonium chloride.